AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that Survivors Have Heart, a national community-building movement powered by stories of heart attack survivors and their loved ones, will return for its third year.

Bob Harper and AstraZeneca Bring Virtual Series to Heart Attack Survivors to Inspire Others with Stories About Second Chances

Is  (AZN) Outperforming Other Medical Stocks This Year?

Is AstraZeneca (AZN) Stock Outpacing Its Medical Peers This Year?

Abbott Labs

Eli Lilly

These healthcare leaders give you a relatively low-risk way to invest in the fight against COVID-19.

Have $5,000? 3 Coronavirus Stocks You Can Buy in July Without Losing Any Sleep

Moderna

Johnson & Johnson

Pfizer

AstraZeneca, Johnson & Johnson, Merck, and Pfizer will also field questions from lawmakers.

Moderna and Other Coronavirus Vaccine Developers to Testify in Congress July 21

Astrazeneca (AZN) closed at $53.97 in the latest trading session, marking a -0.41% move from the prior day.

Astrazeneca (AZN) Stock Moves -0.41%: What You Should Know

The FDA accepts AstraZeneca's (AZN) sNDA for Brilinta under a Priority Review to lower subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.

AstraZeneca's sNDA for Brilinta Gets FDA's Priority Review

Sinovac Biotech

The World Health Organization this week said 21 candidate vaccines are in clinical trials at the moment, meaning they are being tested on human volunteers.

Pharma industry balancing accessibility and intellectual property rights in coronavirus vaccine race

AstraZeneca (AZN) and Merck's Lynparza gets approval in the EU for treating patients with germline BRCA-mutated metastatic pancreatic cancer.

AstraZeneca's Lynparza Gets EU Nod for Pancreatic Cancer

It won't be a slam dunk for vaccines to turn the tide against the pandemic.

3 Reasons You Shouldn't Get Your Hopes Too High About COVID-19 Vaccines

Inovio Pharmaceuticals

Novavax

Companies are testing COVID-19 vaccines right now -- if all goes smoothly, more than one may get to market at “warp speed.”

Is There a Coronavirus Vaccine Yet?

BioNTech SE

Shares of Moderna Inc (NASDAQ: MRNA), a frontrunner in the race for a coronavirus vaccine, tumbled Thursday afternoon after a STAT News report suggested there could be a delay in the initiation of a late-stage study.

Revisiting Coronavirus Vaccine Timelines: Moderna Denies Delay, Pfizer Advances Project Lightspeed And More

Gritstone Oncology Inc

iShares Nasdaq Biotechnology ETF

Regeneron Pharmaceuticals

Sanofi

For the most part, biotech and pharmaceutical companies are involved in the lengthy process of getting their drug candidates to market through clinical trials.

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Merck

Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years.

Wall Street shifts bets to big pharma as COVID-19 vaccine race progresses

Alibaba

Kimberly-Clark

Coca-Cola

Procter & Gamble

Toyota Motor

Unilever

These international stocks offer investors geographically diversified exposure and get a bigger bump as countries open up for business.

7 International Stocks to Buy as the World Economy Restarts

Around a dozen companies are developing a vaccine for the deadly coronavirus disease.

FDA Issues Guidance for Coronavirus Vaccine Developers

Moderna was seen as the leader in the COVID-19 vaccine race -- now it’s sharing the limelight.

What Does AstraZeneca's COVID-19 Vaccine Push Mean for Moderna?

The Food and Drug Administration (FDA) issued new rules on Tuesday for the companies developing COVID-19 vaccines. "While the FDA is committed to help expedite this work, we will not cut corners in our decision making, and we're making clear in our guidance what are the data that we need, that should be submitted, to meet our regulatory standards of approval," FDA commissioner Dr.

FDA issues rules for coronavirus vaccine developers

Here's the "Official" Leader in the COVID-19 Vaccine Race

AbbVie

Amgen

Bristol-Myers

Novartis

The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

Canada federal court dismisses drugmakers' plea challenging drug price rules

Not as quickly as anyone would like, but possibly sooner than some expect.

When Can I Get a Coronavirus Vaccine?

Telesis Bio Inc

Developing a COVID-19 vaccine in record time will be tough. Producing enough to end the pandemic will be the biggest medical manufacturing feat in history.

Vaccine makers face biggest medical manufacturing challenge in history

AstraZeneca has signed its tenth supply-and-manufacturing deal for its experimental COVID-19 vaccine with a Scotland-backed firm as the British drugmaker ramps up efforts for wider trials of the potential treatment.

AstraZeneca taps Scottish firm for 10th COVID-19 vaccine supply deal

The results indicate that a prime dose plus a booster notably increases its effect.

AstraZeneca COVID-19 Vaccine Shows Promise in 2-Dose Animal Trial

GlaxoSmithKline

Globally, there are more than 100 vaccines under development - with nine of them in human clinical trials already.

Who's Ahead In Finding A COVID-19 Vaccine?

Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.

Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay

News for AstraZeneca Stock (AZN)